Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other financing activities (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 9 years of Other financing activities data on record, last reported at $8000.0 in Q4 2025.

  • For Q4 2025, Other financing activities rose 136.36% year-over-year to $8000.0; the TTM value through Dec 2025 reached $687000.0, down 15.81%, while the annual FY2025 figure was $687000.0, 15.81% down from the prior year.
  • Other financing activities reached $8000.0 in Q4 2025 per AMPH's latest filing, up from $4000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $10.4 million in Q3 2023 and bottomed at -$22000.0 in Q4 2024.
  • Average Other financing activities over 5 years is $876466.7, with a median of $252000.0 recorded in 2024.
  • Peak YoY movement for Other financing activities: crashed 104.49% in 2024, then soared 25400.0% in 2025.
  • A 5-year view of Other financing activities shows it stood at $308000.0 in 2021, then plummeted by 99.03% to $3000.0 in 2022, then soared by 16233.33% to $490000.0 in 2023, then plummeted by 104.49% to -$22000.0 in 2024, then soared by 136.36% to $8000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $8000.0 in Q4 2025, $4000.0 in Q3 2025, and $253000.0 in Q2 2025.